Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) Revenue (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Revenue for 6 consecutive years, with $121.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 26.5% to $121.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $427.5 million, a 39.97% increase, with the full-year FY2025 number at $427.5 million, up 39.97% from a year prior.
  • Revenue was $121.0 million for Q4 2025 at GeneDx Holdings, up from $116.7 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $121.0 million in Q4 2025 to a low of -$722000.0 in Q2 2021.
  • A 5-year average of $66.7 million and a median of $61.9 million in 2022 define the central range for Revenue.
  • Peak YoY movement for Revenue: surged 5109.56% in 2022, then plummeted 35.96% in 2023.
  • GeneDx Holdings' Revenue stood at $57.8 million in 2021, then grew by 6.14% to $61.4 million in 2022, then fell by 6.41% to $57.4 million in 2023, then soared by 66.57% to $95.6 million in 2024, then rose by 26.5% to $121.0 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Revenue are $121.0 million (Q4 2025), $116.7 million (Q3 2025), and $102.7 million (Q2 2025).